Aptargroup Stock Price, News & Analysis

AptarGroup, Inc. (NYSE: ATR) has announced a quarterly cash dividend of $0.38 per share, with a payment date set for May 25, 2023 for shareholders on record as of May 4, 2023. The company, based in Crystal Lake, Illinois, specializes in drug delivery and consumer product dispensing solutions across various markets, including pharmaceuticals and personal care. Additionally, Aptar will conduct a conference call on April 28, 2023, at 8:00 a.m. CT to discuss its Q1 2023 results. Interested parties can access the live webcast through the company's Investors page.

AptarGroup, Inc. (NYSE: ATR) has released a recast of financial information following a strategic segment realignment of its reporting segments, focusing on Aptar Closures and Aptar Beauty. The recast covers the past two years of performance for these segments, while the financials for Aptar Pharma remain unchanged. The detailed financial information is accessible in the company's Form 8-K filed on April 13, 2023. Aptar is recognized for its innovative solutions in drug delivery, consumer product dispensing, and active material sciences, catering to various industries including pharmaceuticals and beauty. Headquartered in Crystal Lake, Illinois, Aptar employs 13,500 people across 20 countries.

AptarGroup, Inc. (NYSE: ATR) has been recognized on the CDP Supplier Engagement Leaderboard for the third consecutive year, positioning itself among the top 8% of companies evaluated for climate change engagement. Aptar received an ‘A’ rating, surpassing the North America regional average of ‘C’ and the plastic product manufacturing average of ‘C-‘. The company actively collaborates with suppliers to reduce emissions, focusing on the significant scope 3 emissions from purchased goods, particularly plastics. Additionally, Aptar aims to enhance its supply chain diversity through its newly launched Supplier Diversity Program.

AptarGroup, Inc. (NYSE: ATR) has updated its science-based targets for emissions reduction, aligning with a goal to limit global temperature rise to 1.5° Celsius by 2030. Originally set in 2020 to align with a well below 2°C scenario, the targets have been revised to demonstrate increased ambition. The company aims to reduce absolute Scope 1 and 2 greenhouse gas (GHG) emissions by 82% and Scope 3 emissions by 14% by 2030, using 2019 as the base year. Additionally, Aptar plans to source 100% renewable electricity by 2030. These commitments have been validated by the Science Based Targets initiative (SBTi). Aptar emphasizes its commitment to sustainability through innovative practices.

AptarGroup, Inc. (NYSE: ATR) announced the appointment of Julie Xing to its Board of Directors. With over 20 years of experience in sectors like pharmaceuticals and medtech, Julie aims to inspire sustainable growth in challenging markets. She previously served as Executive Chair of Mundipharma China and held various leadership roles at Eli Lilly. Aptar's President and CEO, Stephan B. Tanda, emphasized the value of her insights into the pharmaceutical market, particularly in Asia. The company celebrates diversity on its board, with 45% female representation. Julie holds a Ph.D. in Biology from Hong Kong University.

AptarGroup, Inc. (NYSE:ATR) reported a net income of $59 million for Q4 2022, a 2% year-over-year increase. While reported sales dipped 2% to $796 million, core sales grew 4%, driven by strong performance in the pharma and beauty segments. Adjusted EBITDA fell 4% to $147 million. For the full year, net income decreased 2% to $239 million, but adjusted earnings per share rose 5% to $3.79. The company completed its 29th consecutive year of increasing dividends, with $99 million returned to shareholders in 2022. Aptar anticipates continued momentum in 2023, focusing on efficiencies and growth in key markets.

AptarGroup, Inc. (NYSE: ATR) has once again secured a Platinum rating from EcoVadis, positioning it among the top 1% of over 90,000 companies evaluated across various industries. This recognition highlights Aptar's commitment to sustainability in environmental stewardship, labor rights, ethics, and sustainable procurement.

CEO Stephan B. Tanda stated that this achievement underscores the company's dedication to ethical practices and a circular economy. The EcoVadis rating methodology is based on international sustainability standards, enhancing Aptar’s reputation as a leader in eco-friendly solutions.

Aptar Pharma, a leader in drug delivery systems and part of AptarGroup (NYSE: ATR), has launched the APF Futurity nasal spray pump, the first metal-free, multidose nasal spray designed for over-the-counter formulations. This pump, certified as highly recyclable by cyclos-HTP, minimizes recycling challenges and promotes sustainability. Made from polyolefin materials without metal components, APF Futurity supports the global shift towards eco-friendly products. The innovative design, based on proven technology, delivers consistent dosing without compromising performance. The product will be unveiled at Pharmapack 2023 in Paris on February 1-2, 2023.